Novo Nordisk A/S
NONOF
$136.96
-$1.03-0.75%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 31.76% | 34.73% | 34.69% | 26.70% | 19.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.76% | 34.73% | 34.69% | 26.70% | 19.38% |
| Cost of Revenue | 30.51% | 31.22% | 29.05% | 26.85% | 15.77% |
| Gross Profit | 31.99% | 35.39% | 35.77% | 26.67% | 20.08% |
| SG&A Expenses | 14.91% | 22.62% | 24.90% | 17.97% | 14.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 113.57% | 174.88% | 88.31% | 28.68% | 37.22% |
| Total Operating Expenses | 25.43% | 29.80% | 30.01% | 25.09% | 18.14% |
| Operating Income | 40.08% | 41.19% | 40.96% | 28.84% | 21.06% |
| Income Before Tax | 38.99% | 52.81% | 55.17% | 40.57% | 23.87% |
| Income Tax Expenses | 46.61% | 58.53% | 58.46% | 37.79% | 21.70% |
| Earnings from Continuing Operations | 37.16% | 51.42% | 54.37% | 41.26% | 24.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.16% | 51.42% | 54.37% | 41.26% | 24.39% |
| EBIT | 40.08% | 41.19% | 40.96% | 28.84% | 21.06% |
| EBITDA | 40.25% | 41.14% | 39.39% | 29.59% | 22.26% |
| EPS Basic | 38.34% | 52.90% | 56.07% | 42.95% | 25.97% |
| Normalized Basic EPS | 46.63% | 53.51% | 55.99% | 43.27% | 26.58% |
| EPS Diluted | 38.33% | 52.90% | 56.09% | 42.97% | 25.97% |
| Normalized Diluted EPS | 46.71% | 53.57% | 56.03% | 43.29% | 26.56% |
| Average Basic Shares Outstanding | -0.90% | -0.98% | -1.06% | -1.14% | -1.22% |
| Average Diluted Shares Outstanding | -0.96% | -1.02% | -1.08% | -1.15% | -1.20% |
| Dividend Per Share | 43.18% | 57.68% | 57.68% | 19.58% | 19.58% |
| Payout Ratio | 0.13% | 0.02% | -0.19% | -0.11% | -0.13% |
